Degarelix for newly diagnosed advanced prostate cancer

Review question

How does degarelix, a newer drug that treats prostate cancer by lowering male sex hormone levels, compare to existing medications for newly diagnosed advanced prostate cancer? 

Background

There is no cure if prostate cancer has spread outside of the prostate gland to lymph nodes or to the bones. In such a situation, hormonal therapy that lowers levels of the male sex hormone testosterone can slow down cancer growth. Testosterone levels are regulated by complicated mechanisms that involve a hormone known as gonadotropin-releasing hormone (GnRH), which is present in men at different levels at different times of the day. It is understood that giving men with prostate cancer high levels of medications that increase GnRH levels first raises testosterone levels, and then drops them to very low levels. These medications are commonly used to treat men with prostate cancer that has spread outside the prostate. Degarelix is a newer drug known as a GnRH antagonist, which blocks receptors in the brain and thereby lowers testosterone levels immediately.

Study characteristics

We included randomized controlled trials (studies in which participants are assigned to one of two or more treatment groups using a random method) comparing degarelix and standard hormonal therapy in men with newly diagnosed advanced prostate cancer. The evidence is current to September 2020 for electronic databases, to October 2020 for trial registries, and to December 2020 for conference proceedings.

Key results

We found 11 studies that were eligible for inclusion in the review, but none of these studies evaluated the risk of dying from any cause or dying from prostate cancer. There may be no difference between degarelix and standard hormonal therapy in serious unwanted effects and quality of life. The effects of degarelix on cardiovascular issues such as the risk of a heart attack or stroke are uncertain; while one study suggested that the risk may be reduced with degarelix, it had major issues, in particular that it was conducted in men at high risk for such problems. We found that degarelix therapy likely results in an increase in the occurrence of pain at the injection site.

Certainty of the evidence

The certainty of evidence for the various outcomes ranged from moderate to very low. There is a need for additional, better designed studies to further understand the effects of degarelix for newly diagnosed advanced prostate cancer. 

Authors' conclusions: 

We did not find trial evidence for overall survival or cancer-specific survival comparing degarelix to standard androgen suppression, but serious adverse events and quality of life may be similar between groups. The effects of degarelix on cardiovascular events are very uncertain as the only eligible study had limitations, was small with few events, and was conducted in a high-risk population. Degarelix likely results in an increase in injection site pain compared to standard androgen suppression therapy. Maximum follow-up of included studies was 14 months, which is short. There is a need for methodologically better designed and executed studies with long-term follow-up evaluating men with metastatic prostate cancer.

Read the full abstract...
Background: 

Degarelix is a gonadotropin-releasing hormone antagonist that leads to medical castration used to treat men with advanced or metastatic prostate cancer, or both. It is unclear how its effects compare to standard androgen suppression therapy.

Objectives: 

To assess the effects of degarelix compared with standard androgen suppression therapy for men with advanced hormone-sensitive prostate cancer.

Search strategy: 

We searched multiple databases (CENTRAL, MEDLINE, Embase, Scopus, Web of Science, LILACS until September 2020), trial registries (until October 2020), and conference proceedings (until December 2020). We identified other potentially eligible trials by reference checking, citation searching, and contacting study authors.

Selection criteria: 

We included randomized controlled trials comparing degarelix with standard androgen suppression therapy for men with advanced prostate cancer.

Data collection and analysis: 

Three review authors independently classified studies and abstracted data from the included studies. The primary outcomes were overall survival and serious adverse events. Secondary outcomes were quality of life, cancer-specific survival, clinical progression, other adverse events, and biochemical progression. We used a random-effects model for meta-analyses and assessed the certainty of evidence for the main outcomes according to GRADE.

Main results: 

We included 11 studies with a follow-up of between three and 14 months. We also identified five ongoing trials.

Primary outcomes

Data to evaluate overall survival were not available. 

Degarelix may result in little to no difference in serious adverse events compared to standard androgen suppression therapy (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.62 to 1.05; low-certainty evidence; 2750 participants). Based on 114 serious adverse events in the standard androgen suppression group, this corresponds to 23 fewer serious adverse events per 1000 participants (43 fewer to 6 more). We downgraded the certainty of evidence for study limitations and imprecision.

Secondary outcomes

Degarelix likely results in little to no difference in quality of life assessed with a variety of validated questionnaires (standardized mean difference 0.06 higher, 95% CI 0.05 lower to 0.18 higher; moderate-certainty evidence; 2887 participants), with higher scores reflecting better quality of life. We downgraded the certainty of evidence for study limitations.

Data to evaluate cancer-specific survival were not available.

The effects of degarelix on cardiovascular events are very uncertain (RR 0.15, 95% CI 0.04 to 0.61; very low-certainty evidence; 80 participants). We downgraded the certainty of evidence for study limitations, imprecision, and indirectness as this trial was conducted in a unique group of high-risk participants with pre-existing cardiovascular morbidities.

Degarelix likely results in an increase in injection site pain (RR 15.68, 95% CI 7.41 to 33.17; moderate-certainty evidence; 2670 participants). Based on 30 participants per 1000 with injection site pain with standard androgen suppression therapy, this corresponds to 440 more injection site pains per 1000 participants (192 more to 965 more). We downgraded the certainty of evidence for study limitations.

We did not identify any relevant subgroup differences for different degarelix maintenance doses.